Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | CCR2 | P41597 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MITF | O75030 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2319263 | 0.92 | HPGD (0.65) | HPGDCYP1A2CYP3A4CYP2C19CCR2 | |
| SCHEMBL2312343 | 0.87 | MEN1 (0.58) | HPGDCYP1A2CYP3A4CYP2C19CCR2 | |
| SCHEMBL3358582 | 0.87 | MITF (0.52) | HPGDCYP1A2CYP3A4CYP2C19MEN1 | |
| SCHEMBL3360184 | 0.87 | GAA (0.56) | HPGDCYP1A2CYP3A4CYP2C19MEN1 | |
| SCHEMBL3844596 | 0.87 | MEN1 (0.52) | HPGDCYP1A2CYP3A4CYP2C19CCR2 | |
| SCHEMBL6940724 | 0.86 | MEN1 (0.61) | HPGDCYP1A2CYP3A4CYP2C19MEN1 | |
| SCHEMBL6944275 | 0.86 | KMT2A (0.65) | HPGDCYP1A2CYP3A4CYP2C19MEN1 | |
| SCHEMBL3358491 | 0.84 | MEN1 (0.55) | HPGDCYP1A2CYP3A4CYP2C19CCR2 | |
| SCHEMBL6939496 | 0.84 | MEN1 (0.63) | HPGDCYP1A2CYP3A4CYP2C19CCR2 | |
| SCHEMBL3848413 | 0.84 | CA2 (0.50) | HPGDCYP1A2CYP3A4CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105283-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20080255161-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. | 2008-10-16 | — | — | US | disclosed |
| EP-1080069-B1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-03-19 | — | — | EP | disclosed |
| US-20020193614-A1 | Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-12-19 | — | — | US | disclosed |
| US-6384080-B1 | TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-07 | — | — | US | disclosed |
| CN-1305454-A | Anthranilic acid derivatives as inhibitors of CGMP phosphodiesterase | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-07-25 | — | — | CN | disclosed |
| EP-1080069-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999054284-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193614-A1 | Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase | PDE3A, PDE2A, PDE5A | HPGD 76/4885CYP1A2 137/4885CYP3A4 853/4885 |
| US-20080255161-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, ECHS1 | HPGD 276/4885CYP1A2 673/4885CYP3A4 422/4885 |
| US-20090105283-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, ECHS1 | HPGD 276/4885CYP1A2 673/4885CYP3A4 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.